FDA Approves New Drug for Schizophrenia, Bipolar Disorder

Share this content:
FDA Approves New Drug for Schizophrenia, Bipolar Disorder
FDA Approves New Drug for Schizophrenia, Bipolar Disorder

FRIDAY, Sept. 18, 2015 (HealthDay News) -- A new antipsychotic drug to treat schizophrenia and bipolar disorder in adults has been approved by the U.S. Food and Drug Administration. The drug, Vraylar (cariprazine), is a capsule taken once a day.

The drug's effectiveness in treating schizophrenia was tested in 1,754 patients in three six-week clinical trials. It was shown to reduce schizophrenia symptoms compared to a placebo. The most commonly reported side effects in the schizophrenia trials were tremor, slurred speech, and involuntary muscle movements.

In three three-week trials involving 1,037 bipolar patients, Vraylar reduced disorder symptoms, the FDA said. The most common drug-related side effects in the bipolar disorder trials included tremor, slurred speech, akathisia, dyspepsia, vomiting, drowsiness, and restlessness.

All FDA-approved drugs for schizophrenia and bipolar disorder must carry a black-box warning indicating an increased risk of death if these drugs are used by older people with dementia-related psychosis, the agency noted.

The drug's maker, Forest Labs, and distributor, Actavis Pharma, are based in New Jersey.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Disabling Injury, Illness Less Likely for Elderly Who Exercise

Disabling Injury, Illness Less Likely for Elderly Who ...

And likely to recover more quickly if injury or illness occurs

More Evidence of Abdominal Fat, Poor Cardiovascular Health Link

More Evidence of Abdominal Fat, Poor Cardiovascular Health ...

Adipose tissue imaging may outperform body mass index for cardiovascular risk assessment

is free, fast, and customized just for you!

Already a member?

Sign In Now »